All In Biotech

Drug Trial Radar · NCT06469944

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma): Substudy 06C

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Sep 20, 2024

Primary completion

Sep 12, 2029

Study completion Sep 12, 2029

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jun 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for investigational agents in combination with chemotherapy and immunotherapy. There is no formal hypothesis in this study.

Conditions

  • Gastroesophageal Junction
  • Gastroesophageal Adenocarcinoma
  • Esophageal Neoplasms
  • Esophageal Cancer

Interventions

  • PembrolizumabBiological

    Administered via intravenous (IV) infusion.

  • Sacituzumab Tirumotecan (sac-TMT)Biological

    Administered via IV infusion.

  • CapecitabineDrug

    Administered via oral tablet.

  • LeucovorinDrug

    Administered via IV infusion.

  • LevoleucovorinDrug

    Administered via IV infusion.

  • 5-Fluorouracil (5-FU)Drug

    Administered via IV infusion

  • OxaliplatinDrug

    Administered via IV infusion

  • Patritumab DeruxtecanBiological

    Administered via IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Lead-in Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)Time frame: Up to approximately 28 days
  2. Safety Lead-in Phase: Number of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 28 days
  3. Safety Lead-in Phase: Number of Participants Who Discontinued Study Intervention Due to an AETime frame: Up to approximately 28 days
  4. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 28 months

Locations

50 sites in 12 countries. Site status is shown where the registry gives one.

  • University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927)

    Tucson, Arizona · Recruiting

  • UCLA Hematology/Oncology - Santa Monica ( Site 6905)

    Los Angeles, California · Recruiting

  • Norton Hospital-Norton Cancer Institute - Downtown ( Site 6900)

    Louisville, Kentucky · Completed

  • The Cancer and Hematology Centers ( Site 6912)

    Grand Rapids, Michigan · Recruiting

  • Hematology-Oncology Associates of Central NY, P.C. ( Site 6925)

    East Syracuse, New York · Recruiting

  • Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 6907)

    New York, New York · Completed

  • UPMC Hillman Cancer Center-UPMC ( Site 6904)

    Pittsburgh, Pennsylvania · Recruiting

  • University of Texas MD Anderson Cancer Center ( Site 6920)

    Houston, Texas · Recruiting

  • ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 6300)

    São Paulo, Brazil · Recruiting

  • IBCC - Instituto Brasileiro de Controle do Câncer ( Site 6304)

    São Paulo, Brazil · Recruiting

  • Liga Norte Riograndense Contra o Câncer ( Site 6303)

    Natal, Rio Grande do Norte, Brazil · Recruiting

  • Hospital Nossa Senhora da Conceição ( Site 6301)

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Bradford Hill Norte ( Site 6407)

    Antofagasta, Chile · Recruiting

  • Clínica Puerto Montt ( Site 6409)

    Port Montt, Los Lagos Region, Chile · Recruiting

  • Centro de Investigación del Maule ( Site 6408)

    Talca, Maule Region, Chile · Completed

  • FALP-UIDO ( Site 6400)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Centro de Oncología de Precisión-Oncology ( Site 6404)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Clínica UC San Carlos de Apoquindo ( Site 6405)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Bradfordhill-Clinical Area ( Site 6401)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Beijing Cancer hospital-Digestive Oncology ( Site 5500)

    Beijing, Beijing Municipality, China · Recruiting

  • The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army ( Site 5501)

    Fuzhou, Fujian, China · Recruiting

  • The First Affiliated hospital of Xiamen University ( Site 5503)

    Xiamen, Fujian, China · Recruiting

  • Henan Cancer Hospital ( Site 5504)

    Zhengzhou, Henan, China · Recruiting

  • The First Affiliated Hospital of Nanchang University ( Site 5514)

    Nanchang, Jiangxi, China · Recruiting

  • Fudan University Shanghai Cancer Center ( Site 5513)

    Shanghai, Shanghai Municipality, China · Active not recruiting

  • Xinjiang Medical University Cancer Hospital - Urumqi ( Site 5506)

    Ürümqi, Xinjiang, China · Active not recruiting

  • Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 5510)

    Hangzhou, Zhejiang, China · Recruiting

  • CHU-BREST Cavale Blanche ( Site 5104)

    Brest, Finistere, France · Recruiting

  • Pitie Salpetriere University Hospital-Hepato-Gastro-Enterology ( Site 5102)

    Paris, Île-de-France Region, France · Recruiting

  • CIC. ( Site 5100)

    Lille, Nord, France · Recruiting

  • NCT-Department of Medical Oncology ( Site 6809)

    Heidelberg, Baden-Wurttemberg, Germany · Recruiting

  • HOPE Hamburg/Norddeutsches Studienzentrum fuer Innovative Onkologie ( Site 6807)

    Erdgeschoss, Free and Hanseatic City of Hamburg, Germany · Recruiting

  • Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 6802)

    Düsseldorf, North Rhine-Westphalia, Germany · Completed

  • Ospedale San Raffaele-Oncologia Medica ( Site 5202)

    Milan, Italy · Recruiting

  • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 5207)

    Meldola, Emilia-Romagna, Italy · Recruiting

  • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 5200)

    Milan, Lombardy, Italy · Recruiting

  • Azienda Ospedaliero Universitaria Pisana ( Site 5206)

    Pisa, Tuscany, Italy · Recruiting

  • Oslo universitetssykehus, Radiumhospitalet ( Site 6501)

    Oslo, Norway · Recruiting

  • Asan Medical Center-Department of Oncology ( Site 5901)

    Seoul, South Korea · Recruiting

  • Samsung Medical Center-Division of Hematology/Oncology ( Site 5900)

    Seoul, South Korea · Recruiting

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.